MENDUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.507 SEK | +6.07% |
|
+6.29% | -3.06% |
| 05-17 | Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024 | |
| 05-17 | Mendus AB Announces Board Changes | CI |
Presentation Operator MessageOperator (Operator)Welcome to Mendus Q1 report 2024. [Operator In...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Calendar
23/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.06% | 48.48M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- IMMU Stock
- News Mendus AB
- Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024
